報價延遲最少15分鐘:2026/03/28 09:59 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
10.85 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.17/--
|
|
企業價值
579.78M
|
| 資產負債 |
|
每股賬面淨值
3.47
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447. |
